COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (USA)
Inventor
Teesalu, Tambet
Ruoslahti, Erkki
Robertson, Gregory, T.
Abstract
in vivo in vivoMycobacterium tuberculosis Mycobacterium tuberculosis (Mtb) when delivered within the nanoparticles is less than the amount of the same antimicrobial delivered alone.
A61K 38/03 - Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Disclosed is a gas sensing apparatus which includes a gas sensor, a modulator, and a processor. A gas sensitive property affects an output signal of the gas sensor and is sensitive to a gas of interest with a sensitivity dependent on a gas sensor parameter. The modulator is configured in operation to modulate the gas sensor parameter at a modulation frequency. The processor is configured in operation to receive the output signal of the gas sensor and to identify or selectively emphasise main and/or higher harmonics of the modulation frequency in the output signal of the gas sensor for sensing of the gas of interest. The modulation has a period less than an average gas adsorption time constant of the gas sensor. A method of gas detection is also disclosed.
The present invention concerns new surface-active polyethylene glycol)-derived hydrogels that are crosslinked by using thiol-Michael addition and a crosslinker. The new concept of preparing thermally responsive hydrogels with a thin active surface layer relies on the forced emulsion formation and sedimentation from the aqueous prepolymer solution by using a crosslinker that is engineered to serve as an antisolvent for the prepolymer while at the same time exhibiting a suitable solubility profile in the sedimented hydrogel layer with respect to the supernatant aqueous phase. The solubility of the crosslinker is higher in the supernatant aqueous phase as compared to the sedimented hydrogel phase. This leads to different concentrations of crosslinker at the bottom and interfacial layers of the hydrogel, different degrees of crosslinking, as well as a higher equilibrium water concentration in the top active layer.
C08J 3/24 - Crosslinking, e.g. vulcanising, of macromolecules
C07C 67/08 - Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
G02F 1/01 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour
C08G 65/332 - Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides or esters thereof
The invention concerns colostrum and, in particular, colostrum in tablet form, as well as methods to produce such tablets. A method is provided for making colostrum tablets, the method comprising: providing colostrum powder; wet granulating the colostrum powder; dry mixing the granulated colostrum powder with microcrystalline cellulose; adding a lubricant; and compressing the resultant mix.
The present invention provides for a method of prognosing preeclampsia in a pregnant subject wherein the method comprises measuring the level of at least three biomarkers in a sample from the subject; optionally determining at least one clinical cofactor from the subject; generating a prediction value, wherein the prediction value indicates whether the subject will develop or will not develop preeclampsia during the ongoing pregnancy; the prediction value being based on the levels of the at least three biomarkers in the sample from the subject and optionally based on the at least one clinical cofactor.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Disclosed herein are methods for treating metabolic syndrome in a subject using a vitamin D receptor agonist. A preferred vitamin D receptor agonist for the present invention is elocalcitol.
An analysis device (100, 200, 300) for analysing a liquid sample (130) for one or more analytes (141-145) is proposed, wherein the device (100, 200, 300) comprises two or more analytic regions (123, 126, 128a) and one or more non-analytic regions (112); each of the analytic regions (123, 126, 128a) is provided as a sample interaction region and/or a detection region for the one or more analytes (141-145); the two or more analytic regions (123, 126, 128a) and the one or more non-analytic regions (112) are provided in one or more substrates in one or more planes; at least one of the two or more analytic regions (123, 126, 128a) is formed by a porous material made from particles and a binder; and the two or more analytic regions (123, 126, 128a) being separated from the one or more non-analytic regions (112) by diffusion barriers (113) for fluid in the one or more analytic regions (123, 126, 128a) corresponding analysis arrangement (1000), a method of producing a corresponding analysis device, and a corresponding analysis method are also provided.
The invention relates to novel membrane-permeable constructs and membrane-permeable constructs for use in the transport of cargo across a lipid membrane and subsequent delivery of said cargo into a cell. The cargo may be mRNA and the cell may be in vivo, such as cell of the spleen. Also provided are pharmaceutical compositions comprising the membrane- permeable constructs and use thereof in methods of raising an immune response in a subject.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Polypeptides that traverse the blood-brain-barrier (BBB) are disclosed. The peptide can serve as BBB-traversing transport vehicles for delivering active agents from the circulation into across the BBB to contact cells and tissues within the CNS and/or brain. Therefore, composition of conjugates including polypeptides that traverse the BBB, conjugated with one or more active agents are provided. The BBB-traversing peptides can be a fusion protein that includes one or more additional domains such as a targeting moiety, a linker, an active agent, a purification tag, or any combination thereof. Exemplary BBB- traversing peptides include polypeptides having an amino acid sequence RRVISRAKLAAAL (SEQ ID NO:1), or a functional variant thereof, or the amino acid sequence of CVGTNCY (SEQ ID NO:2).
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
C07K 14/435 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/02 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A hybrid computing system configured to estimate a derivative of a parameter-dependent physical quantity that is dependent on a first control parameter θ of a parameterised quantum evolution executed by the quantum computing system. The classical computing system determines, based on an input bounding value and phase-correction value, a subset multiset of shift-values which define an equivalent subset multiset of trial control parameter values and corresponding weighting values and summation factors such that the trial control parameter values obey a targeted probability distribution. The quantum computing system executes the parameterised quantum evolution at the trial control parameter values and measures a parameter-dependent physical quantity for each trial control parameter value. On the classical computing system, the measurement results from these measurements are combined with the weighting values and summation factors to calculate at an estimate of a phase-correction-scaled derivative of the parameter-dependent physical quantity.
G06N 10/20 - Models of quantum computing, e.g. quantum circuits or universal quantum computers
G06N 10/80 - Quantum programming, e.g. interfaces, languages or software-development kits for creating or handling programs capable of running on quantum computers; Platforms for simulating or accessing quantum computers, e.g. cloud-based quantum computing
11.
SHIFT RULE FOR GRADIENT DETERMINATION IN PARAMETERISED QUANTUM EVOLUTIONS
A hybrid computing system comprising a quantum computing system and a classical computing system, the quantum computing system comprising a quantum system having one or more quantum devices. The hybrid computing system is configured to estimate a derivative of a parameter-dependent physical quantity that is dependent on a first control parameter 0 of a parameterised quantum evolution executed by the quantum computing system. The classical computing system determines, based on an input bounding value and phase-correction value, a subset multiset of shift-values which define an equivalent subset multiset of trial control parameter values and corresponding weighting values and summation factors such that the trial control parameter values obey a targeted probability distribution. The quantum computing system executes the parameterised quantum evolution at the trial control parameter values and measures a parameter-dependent physical quantity for each trial control parameter value. On the classical computing system, the measurement results from these measurements are combined with the weighting values and summation factors to calculate at an estimate of a phase-correction-scaled derivative of the parameter-dependent physical quantity. In this way, the derivative can be provided to a gradient-descent optimiser to optimise the control parameters of a quantum algorithm.
A method and apparatus are disclosed for assessing gas exchange of plants. The method includes receiving in a gas analyzer a plurality of test air samples from a leaf chamber corresponding respectively to first and second plant leaf samples received separately and in sequence in the leaf chamber while being exposed to light to form the first and second test air samples, the first and second test air samples being received in sequence in the gas analyzer as an integrated gas stream, and the gas analyzer analyzing the integrated gas stream as it flows therethrough. The measuring apparatus includes a leaf chamber for receiving therein a plant leaf sample to be tested, a pump communicating with the leaf chamber for supplying air thereto, and an analyzer communicating with the leaf chamber for receiving air therefrom and for analyzing the air received.
INSTITUTE OF FUNDAMENTAL TECHNOLOGICAL RESEARCH (Poland)
Inventor
Lanno, Georg-Marten
Kowalczyk, Tomasz
Blonski, Slawomir
Putrinš, Marta
Tenson, Tanel
Korczyk, Piotr
Kogermann, Karin
Abstract
The present invention relates to methods for the encapsulation of bioactive entities, and formation into solid materials. The method comprises encapsulation of a bioactive entity via microfluidics and electrospinning into polymer fibres. The invention also relates to electrospun polymer fibres comprising bioactive entity-containing hydrophilic and/or gel-forming polymer microparticles embedded within fibres of at least one hydrophobic polymer. The invention also relates to a wound dressing comprising the electrospun fibres.
The present invention relates to a method of preparing a nanoparticle comprising at least one cell- penetrating peptide (CPP) and a cargo molecule, said method comprising the steps: preparing a CPP solution comprising a CPP, a dry alcohol; and 1-50% (v/v) of an aprotic solvent; diluting the CPP solution in water to a concentration of 2 to 500 µM, and adding the cargo molecule to the CPP solution to obtain a CPP:CM mixture; whereby nanoparticles comprising CPP and cargo molecule are formed. The invention further relates to a nanoparticle obtained or obtainable by the method, as well as pharmaceutical compositions comprising such nanoparticles.
A61K 47/18 - Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
C07K 14/00 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
15.
IN VITRO FERTILISATION (IVF) EMBRYO VIABILITY AND QUALITY ASSAY
The present invention is based on evidence of non-contact transfer of embryonic RNA transcripts to endometrium in an in vitro embryo-maternal cross-talk model. RNA is taken up by the endometrial cells and the expression of endogenous transcripts is altered as a result. The effect can be seen in endometrial cells treated with embryo derived extracellular vesicles (EVs) or conditioned medium derived from IVF embryos. RNA from EVs derived from human IVF embryos and conditioned culture media from the human IVF embryos have the potential to change the level of endometrial transcripts. Interestingly, only good-prognosis viable embryos, i.e., capable of producing pregnancies, induced the observed effect while non-competent, e.g., degenerated, embryos failed to initiate any changes. Hence, the capability of inducing a change in RNA transcripts can be used to determine quality of IVF embryos and in predicting pregnancy outcome.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
16.
METHOD AND DEVICE FOR MEASURING OR DETERMINING AT LEAST ONE BIOMECHANICAL PARAMETER OF SOFT BIOLOGICAL TISSUES
A method of measuring a biomechanical parameter of soft biological tissue is described. The method includes a pre-measurement process wherein an impulse applying device applies a pre-pressure to a surface of the tissue via an end portion contacting the tissue surface. While maintaining the pre-pressure, the device generates at least two impulses separated by a time interval, each impulse causing the end portion to impart to the tissue an action with certain parameters, each action inducing a response of the tissue. A value of a biomechanical parameter of the tissue is determined from each response induced. A determination is made as to whether the determined values of the biomechanical parameter are sufficiently similar to each other to indicate that the pre-pressure, the parameters of the end portion actions and the time interval are acceptable for use in a measurement process to be conducted on the surface of the tissue.
The present invention relates generally to methods of producing products by bacterial cells. More particularly, the present invention relates to methods of producing products by bacterial cells, the methods comprising a step of irreversibly inactivating an origin of replication in the bacterial cell. The present invention also relates to modified bacterial cells, polynucleotide vectors, and uses thereof for producing products.
Disclosed are compositions, compounds, and methods relating to peptides that can target and home to cancer, tumors, and extracellular matrix. This is based on the discovery of peptides that can specifically bind to fibronectin extra domain B (FN-EDB), tenascin-C C domain (TNC-C), or both.
This invention relates to a vaccine comprising live attenuated Zika virus comprising a partly codon deoptimized viral genome, a Zika virus comprising a partly codon deoptimized viral genome, as well as their use in methods of treatment and prevention of viral infection. is deoptimized along the nonstructural ZIKV coding region. In some embodiments, the non-structural region of the viral genome is codon deoptimized, and preferably one or more of the genes NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 are codon deoptimized.
The present invention provides for a method of prognosing preeclampsia in a pregnant subject wherein the method comprises measuring the level of at least three biomarkers in a sample from the subject; optionally determining at least one clinical cofactor from the subject; generating a prediction value, wherein the prediction value indicates whether the subject will develop or will not develop preeclampsia during the ongoing pregnancy; the prediction value being based on the levels of the at least three biomarkers in the sample from the subject and optionally based on the at least one clinical cofactor.
- 24 - Abstract Method and apparatus for assessing gas exchange of plants A method is disclosed for assessing gas exchange of plants, comprising 5 receiving in a gas analyzer a plurality of test air samples from a leaf chamber corresponding respectively to first and second plant leaf samples received separately and in sequence in the leaf chamber while being exposed to light to form the first and second test air samples, the first and second test air samples being received in sequence in the gas analyzer as an integrated gas stream, and the gas 10 analyzer analysing the integrated gas stream as it flows therethrough. Measuring apparatus for assessing gas exchange of plants is also disclosed, comprising a leaf chamber for receiving therein a plant leaf sample to be tested, a pump communicating with the leaf chamber for supplying air thereto, an analyzer communicating with the leaf chamber for receiving air therefrom and for analysing 15 the air received, wherein the pump is configured to be filled with a single charge of air and to supply plural doses of air from that single charge each for sequentially testing a respective plant leaf sample of a plurality of plant leaf samples. 20 25 30 35
AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (Singapore)
University of Tartu (Estonia)
Inventor
Ng, Lisa Fong Poh
Chan, Yi Hao
Merits, Andres
Utt, Age
Abstract
Provided herein are polypeptides, polynucleotides, expression vectors, infectious clones, virus particles and immunogenic compositions of recombinant alphaviruses which can be used as vaccines. Also provided are methods for eliciting an immune response against alphavirus infection using the immunogenic composition comprising the alphavirus mutants described herein.
The present invention is based on evidence of non-contact transfer of embryonic RNA transcripts to endometrium in an in vitro embryo-maternal cross-talk model. RNA is taken up by the endometrial cells and the expression of endogenous transcripts is altered as a result. The effect can be seen in endometrial cells treated with embryo derived extracellular vesicles (EVs) or conditioned medium derived from IVF embryos. RNA from EVs derived from human IVF embryos and conditioned culture media from the human IVF embryos have the potential to change the level of endometrial transcripts. Interestingly, only good- prognosis viable embryos, i.e., capable of producing pregnancies, induced the observed effect while non- competent, e.g., degenerated, embryos failed to initiate any changes. Hence, the capability of inducing a change in RNA transcripts can be used to determine quality of IVF embryos and in predicting pregnancy outcome.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
A01K 67/00 - Rearing or breeding animals, not otherwise provided for; New breeds of animals
A method of preparing an alcogel for use as a source of fuel includes the steps of hydrolysing at least one tetraalkoxysilane with water in the presence of a solvent and catalyst, wherein the solvent includes at least one alcohol, and wherein the molar ratio (R) of water to alkoxide is greater than 4. The alcogel can then be stored in a hermetically sealed container in order to minimise evaporation of the alcohol, and used as a source of fuel, for example for use when camping.
The present invention provides for a method of prognosing or diagnosing preeclampsia in a subject wherein the method comprises measuring the level of at least four biomarkers in a blood sample from the subject; optionally determining at least one clinical cofactor from the subject; generating a prediction value, wherein the prediction value indicates whether the subject will develop or will not develop preeclampsia or has preeclampsia; the prediction value being based on the levels of the at least four biomarkers in the blood sample from the subject and optionally based on the at least one clinical cofactor.
A method of noninvasively measuring a biomechanical parameter of soft biological tissue, using an impulse applying device comprising a movable testing body having an end portion to be placed in contact with a surface of the tissue, the method comprising a pre-measurement process which comprises: the impulse applying device applying a pre-pressure to the surface of the tissue via the end portion in contact with the surface of the tissue; whilst maintaining said pre-pressure, the impulse applying device generating at least two impulses separated by a time interval, each impulse causing the end portion to impart to the tissue an action with certain parameters, and each of the end portion actions inducing a response of the tissue; determining a value of a biomechanical parameter of the tissue from the response induced by each end portion action; and determining if the values of the biomechanical parameter determined from the response induced by each end portion action are sufficiently similar to each other to indicate that the pre-pressure, the parameters of the end portion actions and the time interval are acceptable for a measurement process to be conducted on the surface of the tissue using the same pre-pressure, a plurality of end portion actions with the same parameters and the same time interval.
Disclosed are compositions, compounds, and methods relating to peptides that can target and home to cancer, tumors, and extracellular matrix. This is based on the discovery of peptides that can specifically bind to fibronectin extra domain B (FN-EDB), tenascin-C C domain (TNC-C), or both.
Disclosed are compositions, compounds, and methods relating to peptides that can target and home to cancer, tumors, and extracellular matrix. This is based on the discovery of peptides that can specifically bind to fibronectin extra domain B (FN-EDB), tenascin-C C domain (TNC-C), or both.
The present invention provides for a membrane-permeable construct for transport of cargo across a lipid membrane and subsequent delivery of cargo into cells, wherein the construct comprises a cell penetrating amino acid sequence and a fatty acid chain attached to the N terminus thereof, wherein the cell penetrating amino acid sequence comprises the sequence of SEQ ID NO: 1, or comprises a modified sequence of SEQ ID NO: 1, wherein the cell penetrating amino acid sequence comprises two or more histidine residues by substitution to its N-terminal part and/or addition to its N-terminus, and wherein the cell penetrating amino acid sequence is optionally chemically modified at the C terminus.
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
A method for producing a carbon nanomaterial for use as a catalyst, including the steps of: (a) providing a precursor which is a source of lignin, (b) heating the precursor to an activation temperature from 700°C to 800°C in the presence of an alkali solution in order to produce an activated precursor, and (c) reacting the activated precursor with a source of nitrogen atoms in order to dope the activated precursor with nitrogen atoms, wherein the precursor is heated in step (b) to the activation temperature at a rate of at least 500°C per minute.
This invention relates to a vaccine comprising live attenuated Zika virus comprising a partly codon deoptimized viral genome, a Zika virus comprising a partly codon deoptimized viral genome, as well as their use in methods of treatment and prevention of viral infection. is deoptimized along the nonstructural ZIKV coding region. In some embodiments, the non-structural region of the viral genome is codon deoptimized, and preferably one or more of the genes NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 are codon deoptimized.
AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (Singapore)
UNIVERSITY OF TARTU (Estonia)
Inventor
Ng, Lisa Fong Poh
Chan, Yi Hao
Merits, Andres
Utt, Age
Abstract
The present invention generally relates to polypeptides, polynucleotides, expression vectors, infectious clones, virus particles and immunogenic compositions of recombinant alphaviruses which can be used as vaccines. The present disclosure also relates to methods for eliciting an immune response against alphavirus infection using the immunogenic composition comprising the alphavirus mutants described herein.
C08F 124/00 - Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a heterocyclic ring containing oxygen
C12P 17/18 - Preparation of heterocyclic carbon compounds with only O, N, S, Se, or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (Singapore)
UNIVERSITY OF TARTU (Estonia)
Inventor
Ng, Lisa Fong Poh
Chan, Yi Hao
Merits, Andres
Utt, Age
Abstract
The present invention generally relates to a recombinant polypeptides comprising an amino acid sequence, or a variant thereof derived from the Chikungunya virus non-structural polyprotein (SEQ ID NO: 1 ) comprising one or more mutations selected from the group consisting of (a) a mutation at a position equivalent to amino acid position 532 of SEQ ID NO: 1, and (b) a mutation at a position equivalent at amino acid position 1050 of SEQ ID NO: 1. Also claimed are polynucleotides, expression vectors, infectious clones, virus particles and immunogenic compositions of recombinant alphaviruses comprising said polypeptides. The present disclosure also relates to methods for eliciting an immune response against alphavirus infection using the immunogenic compositions of alphaviruses mutants described herein.
The present invention relates to a method for forming a capacitor having carbon or metal electrodes and an electrolyte which is also a source of electropolymerisable anions. Applying a sufficiently positive voltage, a thin dielectric layer forms at the positive electrode, enabling the use of cell voltages higher than 3.5 V. The construction and characteristics of capacitors with 5, 6.3, and 10 V of cell voltages, having reduced graphene oxide electrodes and an ionic liquid electrolyte, are shown. Further, a method of forming a capacitor, including the steps of: (a) providing a first electrode; (b) providing a first electrolyte including an anionic compound, wherein said compound includes at least one cyano group or at least one nitrile group; (c) electropolymerising said anionic compound in order to form a dielectric layer on at least part of the first electrode; (d) forming a capacitor including the electrode of step (c), a second electrode and a second electrolyte, which is the same or different to the first electrolyte, is claimed. In a further aspect of the invention, there is provided an electronic device including a capacitor, a transistor or an electrode produced by means of a method as defined above. It is believed that a number of dielectric compounds produced by the method as defined above are new compounds not previously isolated. Accordingly, polytetracyanoborate, polycyani, or polytricyanomethanide.
Electrodes, separators, half-cells, and full cells of electrical energy storage devices are made with electrospinning and isostatic compression. The electrical energy storage device may include electrochemical double layer capacitors (EDLCs, also known as “supercapacitors”), hybrid supercapacitors (“HSCs”), Li-ion capacitors and electrochemical storage devices, Na-ion capacitors and electrochemical storage devices, polymer electrolyte fuel cells, and still other capacitors and electrochemical storage cells.
H01M 8/1081 - Polymeric electrolyte materials characterised by the manufacturing processes starting from solutions, dispersions or slurries exclusively of polymers
H01M 8/1086 - After-treatment of the membrane other than by polymerisation
H01M 8/1004 - Fuel cells with solid electrolytes characterised by membrane-electrode assemblies [MEA]
H01G 11/86 - Processes for the manufacture of hybrid or EDL capacitors, or components thereof specially adapted for electrodes
The application relates to flexible ionic electroactive polymer (IEAP) laminates also known as ionic capacitive laminates (ICLs) particularly used for actuators, sensors or capacitors. More specifically, the invention relates to ICLs capable of fabrication on an industrial scale. An ionic electroactive polymer laminate suitable for use as an actuator is described, comprising opposing planar electrodes separated by an electrode-separating layer, wherein the electrode separating layer comprises a flexible porous reinforcing web suitable for supporting the laminate during fabrication, the electrode- separating layer further including an ion permeable polymer membrane within the pores of the reinforcing web. A method of producing an ionic electroactive polymer laminate suitable for use as an actuator is also described, comprising the steps of producing a planar electrode-separator by supporting a flexible, porous reinforcing web so that it is taught, impregnating the reinforcing web with a membrane solution that includes a polymer suitable for forming an ion permeable membrane, a pore- forming liquid and a solvent, evaporating the solvent to form an ion permeable membrane within the structure of the reinforcing web, the method further including the steps of coating each side of the planar electrode-separator with an electrode solution comprising material suitable for forming electrodes and an electrode solvent, evaporating the electrode solvent to form planar electrodes separated by the electrode-separator.
09 - Scientific and electric apparatus and instruments
16 - Paper, cardboard and goods made from these materials
18 - Leather and imitations of leather
25 - Clothing; footwear; headgear
32 - Beers; non-alcoholic beverages
35 - Advertising and business services
41 - Education, entertainment, sporting and cultural services
Goods & Services
Electronic downloadable publications; Electronic notice boards; Electronic publications, downloadable; Downloadable newspapers and magazines; Reflecting strips for wear, reflecting discs for wear; Reflective safety vests; Eyewear. Paper; Paperboard; Cardboard boxes; Stickers [stationery]; Notepaper; Writing paper; Printed matter, including newspapers, magazines, scrapbooks, almanacs, pamplets, photographs, information materials, calendars, maps, calatogues, prospectuses, books, notebooks, postcards, labels (not of textile), postage stamps, stationery; Office requisites; Teaching materials (except apparatus); Packaging and packaging materials of paper and cardboard; Plastic film for wrapping; Bags [envelopes, pouches] of paper or plastics, for packaging; Luggage tags of paper; Sports trading cards. Casual bags; Sport bags; Backpacks; Suitcases; Baggage tags; Umbrellas. Clothing, sports clothing, tee-shirts, headgear, sports headgear, headbands; Footwear not for sports; Sports shoes. Beers; Mineral and aerated waters and other non-alcoholic beverages; Sports drinks. Business management of sporting facilities [for others]; Advice relating to the business management of sport clubs; Business management in the field of sports; Promoting the goods and services of others by arranging for sponsors to affiliate their goods and services with sports competitions; Promoting the goods and services of others by arranging for sponsors to affiliate their goods and services with sporting activities; Advertising, including promotion of products and services of third parties through sponsoring arrangements and licence agreements relating to international sports' events. Organisation of sports competitions; Production of sporting events; Sport camp services; Sports-park services; Rental of sports equipment, except vehicles; Games equipment rental; Rental of sports grounds; Providing sports facilities; Rental of tennis courts; Health club services [health and fitness training]; Coaching [training]; Sports training; Personal trainer services [fitness training]; Officiating at sports contests; Physical education; Entertainment; Arranging of competitions for education or entertainment; Tutoring; Entertainment provided during intervals of sporting events; Arranging and conducting of courses, seminars and workshops.
40.
METHOD OF FORMING A DIELECTRIC THROUGH ELECTRODEPOSITION ON AN ELECTRODE FOR A CAPACITOR
The present invention relates to a method for forming a capacitor having carbon or metal electrodes and an electrolyte which is also a source of electropolymerisable anions. Applying a sufficiently positive voltage, a thin dielectric layer forms at the positive electrode, enabling the use of cell voltages higher than 3.5 V. The construction and characteristics of capacitors with 5, 6.3, and 10 V of cell voltages, having reduced graphene oxide electrodes and an ionic liquid electrolyte, are shown. Further, a method of forming a capacitor, including the steps of: (a) providing a first electrode; (b) providing a first electrolyte including an anionic compound, wherein said compound includes at least one cyano group or at least one nitrile group; (c) electropolymerising said anionic compound in order to form a dielectric layer on at least part of the first electrode; (d) forming a capacitor including the electrode of step (c), a second electrode and a second electrolyte, which is the same or different to the first electrolyte, is claimed. In a further aspect of the invention, there is provided an electronic device including a capacitor, a transistor or an electrode produced by means of a method as defined above. It is believed that a number of dielectric compounds produced by the method as defined above are new compounds not previously isolated. Accordingly, polytetracyanoborate, polycyani, or polytricyanomethanide.
A method for preparing thin double-structured composite corrosion resistant and/or passivating coatings that consist of a thin metal oxide-hydroxide subcoating prepared by anodizing the metal substrate materials near-surface part and then provided with an atomic layer deposition (ALD) topmost nanocoating, of e.g. oxide, nitride, carbonate, carbide etc. or their mixes or laminates, or laminates with ceramic and metallic layers, or laminates with inorganic or organic polymers and ceramic layers.
C23C 16/00 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition (CVD) processes
C25D 5/48 - After-treatment of electroplated surfaces
C23C 28/04 - Coating for obtaining at least two superposed coatings either by methods not provided for in a single one of main groups , or by combinations of methods provided for in subclasses and only coatings of inorganic non-metallic material
C23C 16/455 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition (CVD) processes characterised by the method of coating characterised by the method used for introducing gases into the reaction chamber or for modifying gas flows in the reaction chamber
C23C 16/48 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition (CVD) processes characterised by the method of coating by irradiation, e.g. photolysis, radiolysis, particle radiation
C23C 16/50 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition (CVD) processes characterised by the method of coating using electric discharges
Lactobacillus fermentum ME-3 strain DSM 14241 for use in preventing, alleviating the symptoms of or treating, alone or as an adjuvant component, a metabolic syndrome related disorder selected from prediabetes, type 2 diabetes and cardiovascular disease. The effect may be achieved by simultaneously: decreasing the level of glycated haemoglobin HbA1c, decreasing or preventing low-grade inflammation on a cellular level and increasing the level of adiponectin.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
A23G 1/42 - Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing paramedical or dietetical agents, e.g. vitamins
A method and device for monitoring a treatment of posture of different body parts in which a local mechanotherapeutic stimulus is applied to a subject (e.g. a human or animal). The device comprises an elastic material 1 which is to be worn over the part of the body, a pressure regulating support 4, a pressure applicator 7 and a pressure sensor 8. The support 4 is fixed to the elastic material 1 and passes over a region where mechanotherapeutic stimulus is to be applied and allows for tension in the support to be varied and to act on a convex rear face of the pressure applicator 7. The sensor 8 is rigidly attached to the pressure applicator 7 and they are together received in a pocket. The sensor senses pressure and hence a stimulus applied to the part as a result of the tension in the support, the sensor being configured to output a signal indicative of the pressure applied, providing the opportunity to change the stimulus to within a given range based on the feedback from the sensor.
A61F 5/01 - Orthopaedic devices, e.g. long-term immobilising or pressure directing devices for treating broken or deformed bones such as splints, casts or braces
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
There is provided inter alia a compound of formula (I), Q-L-P wherein Q is a moiety that binds to the ATP -binding site of a Pim kinase; L is an organic tether that connects Q to P and permits simultaneous binding of Q and P to a Pim kinase; P is a moiety that binds to the protein binding domain of Pim kinase; and wherein the compound of formula (I) is optionally labelled with a fluorophore.
C07D 235/10 - Radicals substituted by halogen atoms or nitro radicals
C07D 239/22 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
45.
METHOD OF TREATMENT USING LACTOBACILLUS FERMENTUM ME-3
The invention provides a composition comprising Lactobacillus fermentum ME-3 strain DSM 14241 for use in preventing, alleviating the symptoms of or treating, alone or as an adjuvant component,a metabolic syndrome related disorder selected from prediabetes, type 2 diabetes and cardiovascular disease. The effect may be achieved by simultaneously:decreasing the level of glycated haemoglobin HbA1c, decreasing or preventing low-grade inflammation on a cellular level and increasing the level of adiponectin.
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 39/06 - Free radical scavengers or antioxidants
A method for preparing thin double-structured composite corrosion resistant and/or passivating coatings that consist of a thin metal oxide-hydroxide subcoating prepared by anodizing the metal substrate materials near-surface part and then provided with an atomic layer deposition (ALD) topmost nanocoating, of e.g. oxide, nitride, carbonate, carbide etc. or their mixes or laminates, or laminates with ceramic and metallic layers, or laminates with inorganic or organic polymers and ceramic layers.
C23C 28/04 - Coating for obtaining at least two superposed coatings either by methods not provided for in a single one of main groups , or by combinations of methods provided for in subclasses and only coatings of inorganic non-metallic material
47.
METHOD OF TREATMENT USING LACTOBACILLUS FERMENTUM ME-3
The invention provides a composition comprising Lactobacillus fermentum ME-3 strain DSM 14241 for use in preventing, alleviating the symptoms of or treating, alone or as an adjuvant component,a metabolic syndrome related disorder selected from prediabetes, type 2 diabetes and cardiovascular disease. The effect may be achieved by simultaneously:decreasing the level of glycated haemoglobin HbA1c, decreasing or preventing low-grade inflammation on a cellular level and increasing the level of adiponectin.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 39/06 - Free radical scavengers or antioxidants
48.
METHYLATION AND MICRORNA MARKERS OF EARLY-STAGE NON-SMALL CELL LUNG CANCER
The present invention is related to a method for detecting neoplastic cells originating from lung tissue with DNA and RNA-based biomarkers whereas the method comprising steps of isolating DNA or RNA from lung tissue or remote body fluids, detecting the methylation state of DNA of one or more, and/or detecting the expression levels of one or more micro-RNAs, thereafter determining the presence of neoplastic cells by comparing the methylation level and/or expression level of the genes with the levels of same genes in non-neoplastic cells, whereas if the methylation or expression level in the cell differs from the normal methylation or expression level in the cell said cell is considered neoplastic. There have been identified genes with altered methylation and microRNAs with aberrant expression in NSCLC.
The present invention involves detection of differential expression of specific microRNAs (miRNAs) in certain biological/pathological conditions, and functional applications of miR-511, miR-193b,miR-99b and other listed miRNAs as markers and targets in cancer and immune system related diseases. The microRNAs are used as an expression modulation targets for influencing proliferative properties of a cell and/or immune functions of an organism.
ESTONIAN NANOTECHNOLOGY COMPETENCE CENTRE (Estonia)
Inventor
Kruve, Anneli
Herodes, Koit
Lõhmus, Rünno
Leito, Ivo
Lõhmus, Ants
Abstract
The present invention relates to a method of spraying the analyte or the effluent comprising the analyte from ionisation source into mass spectrometer whereas into the spray of the effluent is directed additional inner spray of the nebulising gas for breaking the spray of the effluent and for reducing the size of the effluent droplets. For implementing of said method is proposed a injector capillary system where into the external capillary (A) of the outer nebulizer gas is placed the capillary (B) of the analyte or effluent comprising the analyte into which is respectively placed additional third inner capillary (C) or the bundle of inner capillaries of the nebulizer gas where through capillary (C) the nebulising gas is directed into the spray of the effluent.
The present application describes a sensor device used, for example, in robotics, biotechnology, biomedicine and medicine, whereas the sensor device is manufactured from carbon-ionic liquid-polymer composite, comprising at least two separator layers, which are made from carbon-ionic liquid-polymer composite material and comprises at least two electrode layers manufactured of carbon film and separated by a layer manufactured as porous polymer membrane comprising an ionic liquid not having electronic conductivity. At the same time the sensor device acts as actuator, which allows immediate feedback of the actuator curvature, its velocity and change of direction of movement.
The invention concerns novel molecular complexes with photoluminescent probes whose specific association with purine-binding proteins leads to increased emission of long lifetime luminescence, and the application of the probes for monitoring activity of protein kinases (PKs) and other purine-binding proteins, screening of compounds as inhibitors of PKs and characterization of inhibitors targeted to the kinase, and methods of manufacturing of such probes. The invention concerns also the use of the improved method for monitoring activity of protein kinases in living cells, characterization of inhibitors of protein kinases, analysis of protein kinase-based disease biomarkers and other tasks of biological and medical importance.
The present invention prescribes a new sol-gel method of preparing and formation of the metal oxide microtubes. According to the method firstly is prepared the precursor sol from metal oxides or mixtures of metal oxides and alkoxides, thereafter from the precursor sol are extruded the fibres, which are gelatinised afterwards until the inner sol which is less viscous of fibres is converted to thinner wall until alcohol from the precursor is left trough walls. The metal oxide microtubes are applicable as to conduct liquids or gasses, as ionic conductors, as catalyst carriers and as light emitters.
C04B 35/622 - Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
D01D 5/24 - Formation of filaments, threads, or the like with a hollow structure; Spinnerette packs therefor
D01F 9/10 - Man-made filaments or the like of other substances; Manufacture thereof; Apparatus specially adapted for the manufacture of carbon filaments of inorganic material by decomposition of organic substances
54.
THE METHOD OF PREPARATION OF NANOCOLLOIDAL SnO2 WATERSOL AND ITS USES
The present invention concerns nano colloidal water-sol of SnO2, and its use in the preparation of microspheres, micro and nano containers or solid and liquid filled microcapsules. According to the method firstly the stannic oxide is mixed with alcohol and the obtained mixture is poured quickly into the water. The resulting precipitate is transformed into homogeneous liquid whereas the alcohol is removed during transforming process. The aqueous solution is purified with alcohol and concentrated in vacuum at a temperature of 70-85 °C until the water solution becomes viscous syrop-like emulsion of the precursor.
A layered actuator (10) comprising at least two electrode layers (2,4) and an electronically nonconductive membrane (3) in between, where at least one electrode layer (2;4) contains carbide-derived carbon, a polymer material and an ionic liquid. The layered actuator bends due to relocation of the membrane ions when direct current is applied to the electrodes.
ESTONIAN NANOTECHNOLOGY COMPETENCE CENTRE (Estonia)
Inventor
Vlassov, Sergei
Saal, Kristjan
Lõhmus, Rünno
Plaado, Margo
Lõhmus, Ants
Kink, Ilmar
Abstract
The present invention is related to the method and device for measuring the chemical and biological analyte or viscosity and surface tension of the liquid. The device is comprised of a tuning fork type quartz crystal resonator having an associated resonant frequency and the sensing part attached to at least one prong of the resonator. The sensing part is made from low density and high surface area material, e.g. carbon nanotube fibre. Method comprises the immersing of only the sensing part of the device into the liquid, excitation of the sensor with electric field and registration of the changes in resonant frequency due to changes in mass of the sensing part or due to changes in viscosity and surface tension of the liquid.
The present invention finds application in the field of medicine and, in particular, to new compounds particularly active in inhibiting Rac1 member of the Rho family. Pharmaceutical preparations containing them useful for the treatment and/or prevention of heart failure are disclosed as well.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
58.
METHOD OF PREPARATION OF SURFACE COATING OF VARIABLE TRANSMITTANCE AND ELECTRO-OPTICAL APPLIANCE INCLUDING THE SAME
ESTONIAN NANOTECHNOLOGY COMPETENCE CENTRE (Estonia)
Inventor
Timusk, Martin
Järvekülg, Martin
Saal, Kristjan
Lõhmus, Rünno
Kink, Ilmar
Lõhmus, Ants
Abstract
Method of preparation of surface coating of variable transmittance and an electro-optical layered appliance including the same comprises dispersing of liquid crystal microdroplets in hydrolyzable and polymerizable precursors and applying obtained mixture on a surface by spraying. Applying the material to the surface by spraying is intrinsically related to the synthesis processes because the properties of the surrounding environment (i.e. content of water and acidity, UV radiation) and the chemical reactions that take place during spraying have considerable influence on the properties (i.e. driving voltage, thickness of obtained layer). Obtained layered appliance comprises of a matrix material with dispersed microdroplets of liquid crystal obtained by the described method, electrically conductive transparent electrodes with contacts, a dielectric material, substrate and covering layers.
G02F 1/139 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour based on liquid crystals, e.g. single liquid crystal display cells characterised by the electro-optical or magneto-optical effect, e.g. field-induced phase transition, orientation effect, guest-host interaction or dynamic scattering based on orientation effects in which the liquid crystal remains transparent
B05D 1/02 - Processes for applying liquids or other fluent materials performed by spraying
B05D 1/34 - Applying different liquids or other fluent materials simultaneously
C09D 4/00 - Coating compositions, e.g. paints, varnishes or lacquers, based on organic non-macromolecular compounds having at least one polymerisable carbon-to-carbon unsaturated bond
59.
POTATO VIRUS A COAT PROTEIN-BASED VACCINE FOR TREATING MELANOMA AND ITS USE
A vaccine for treating melanoma, comprising at least one melanoma antigen and a viral-like particle comprising potato virus A coat protein. Use of vaccine for treating melanoma, including protein and DNA vaccines, based on potato virus A coat protein.
Actuator comprises at least one layer, composed of nanoporous carbide derived carbon, and containing an electrolyte, such as ionic liquid. The actuator extends linearly when voltage is applied to the actuator. Nanoporous carbide derived carbon layer preferably contains 80 to 100 volume percent of a material having an average pore size is less than 1 nanometer and at least 50 per cent of the total pores volume is from the pores with the size less than 1.1 nanometers. Actuator may comprise two layers of nanoporous materials, separated by membrane of polymer material.
H02N 11/00 - Generators or motors not provided for elsewhere; Alleged perpetua mobilia obtained by electric or magnetic means
F03G 7/00 - Mechanical-power-producing mechanisms, not otherwise provided for or using energy sources not otherwise provided for
61.
METHOD AND A KIT FOR IDENTIFYING A HUMAN WHO HAS THE PREDISPOSITION FOR INCREASED CONSUMPTION OF CARBOHYDRATES AND METHOD FOR MANAGING THE NAMED HUMAN'S DIETARY INTAKE OF NUTRITIONAL ENERGY
The present invention provides a method and a kit for determining the human with genetic predisposition to increased consumption of carbohydrates and to develop metabolic, psychiatric or neurological disease or disorder, or obesity. The invention further pertains to the detection of a human's ADRA2A genotype, and if there will be detected the homozygous nucleotide G at the position C-1291 of the ADRA2A gene, then the named human has a predisposition to increased consumption of carbohydrates and to develop metabolic, psychiatric or neurological diseases or disorders or obesity, and there is a need to decrease the intake of carbohydrates.
ESTONIAN NANOTECHNOLOGY COMPETENCE CENTRE (Estonia)
Inventor
Järvekülg, Martin
Reedo, Valter
Mäeorg, Uno
Kink, Ilmar
Lõhmus, Ants
Abstract
In the current invention a method for the preparation of an oxide material was described that involves bringing the sol onto the substrate, the gelation of the solution and thermal treatment of the gel. Alkoxides are used as precursor mterials for the sol preparation and substrate free structures are employed for the manufacturing of the oxide material. A gel film with thickness ranging from 5 nm to 1 μm is created onto the sol layer. The gelled film is separated into pieces by self organizing and the gelled part is disconnected from the substrate. Substrate free tubular structures with diameters ranging from 0.01-100 μm are formed of the gel film which are then heated at temperature range of 200-1600 C during a period of 5 minutes to 10 hours. The manufactured oxide materials are employed as catalysts, gas sensors, stationary phases of chromatographic columns, composite materials, thermal isolation materials and micro- or nano electronic mechanical systems (MEMS or NEMS) components.
A device that can be attached to a fin of a suf board or similar water craft. The device contains an opening (13) for receiving the fin (3). The device is made of elastic material and the area of the device is at least 1.5 times larger than the area of the fin of the surfboard or similar water craft. In one embodiment, the area of the device is 1.5 to 5 times larger that the area of the fin. In another embodiment, the area of the device is about 3 times larger than the area of the fin. The device may be equipped with clamping means for securely fixing the device to the fin.
The invention relates to a method for introducing changes into a eukaryotic genome in vivo wherein the HPV genome, which comprises HPV replication origin sequence, is used together with HPV early proteins in order to achieve DNA replication in vivo. There is also disclosed a kit for in vivo amplification, excision, translocation and/or inversion of a DNA sequence, which comprises a vector carrying HPV genome or a part of HPV genome including HPV replication origin sequence, and expression vector or vectors encoding HPV early proteins.
A shape changing manipulator comprising a plurality of elements at least partly made of a bending electroactive polymer material, whereby these elements comprise integrated sensing means so as to form self-sensing actuators.
This invention relates to fluorescent probes for identification of compounds binding to protein kinases, for measurement of the affinity of inhibitors of protein kinases, and determination of the active concentration of protein kinases binding to the probe. Bisubstrate-analog character of the probe enables the simultaneous evaluation of inhibitors targeted to both ATP binding site and substrate protein/peptide binding domain of the kinase. High affinity of the probe (Kd = 1.0 nM towards cAMP-dependent protein kinase) affords the application of the enzymes at low concentration which leads to the substantial decrease of the consumption of the kinase. Due to the ability of the conjugates of oligo(D-arginine) with a ATP binding site targeted inhibitors of this invention to bind with high affinity to a wide spectrum of (basophilic) kinases, a single Fluorescent probe is applicable for assessment of inhibitory potency of compounds towards a great number of protein kinases.
C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
67.
SELF-SENSING ACTUATOR AND METHOD OF CONTROLLING THEREOF
A self- sensing actuator of electroactive polymer material such as ionic polymer-metal compound comprises a rigidly fixed part (4) and a moveable part (5) connected to each other. A control signal contact pair (2) for applying a control voltage to the actuator and a first sensor signal contact pair (3) are attached to the moveable part of the actuator. A second sensor signal contact pair (1) for obtaining a reference potential is attached to the rigidly fixed part of the actuator. The shape change of the moveable part during operation of the actuator is determined from the difference of the signals at the two sensor signals contact pairs. A method for controlling the shape of the actuator is also disclosed.
